These findings are supported by prior studies showing that TRPM2 inhibition can alleviate cisplatin‐induced acute kidney injury and ischemia–reperfusion damage via autophagy modulation and ROS suppression (Chen et al. 2025). The gene discussed is TRPM2; the disease is acute kidney injury.